Angiotech and Boston Scientific suffer downgrades over drug-coated stents

VANCOUVER (CP) - Angiotech Pharmaceuticals Inc. and its partner in the drug-coated stent business, Boston Scientific, were downgraded by investment firm Merrill Lynch on Tuesday on concerns about competition and a lack of catalysts for future growth....More